A new paradigm for the prediction of antidepressant treatment response

Dialogues in Clinical Neuroscience

Volumn 11, Issue 4, 2009, Pages 435-446

  Leuchter, Andrew F ^a   Cook, Ian A ^b   Hunter, Aimee M ^b   Korb, Alexander S ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

Antidepressant medication; Antidepressant treatment response (ATR) index; Major depression; Predicting treatment response; Response endophenotype

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ESCITALOPRAM; MIRTAZAPINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VENLAFAXINE;

CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECONOMIC ASPECT; ELECTROENCEPHALOGRAPHY; GENE EXPRESSION; HUMAN; MAJOR DEPRESSION; NONHUMAN; PHENOTYPE; REVIEW; SEIZURE; TREATMENT RESPONSE;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; ELECTROENCEPHALOGRAPHY; GENE EXPRESSION; HEALTH CARE COSTS; HUMANS; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX;

EID: 75749098889     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. Greenberg P, Kessler R, Birnbaum H. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psych. 2003;64:1465-1475.
2. Kessler R, Chiu W, Demler O. Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Arch Gen Psych. 2005;62:617-627.
3. Rush AJ, Trivedi MH, Carmody TJ, et al. One-year clinical outcomes of depressed public sector outpatients: a benchmark for subsequent studies. Biol Psychiatry. 2004;56:6-53.
4. Fochtmann LJ, Gelenberg AJ. Guideline Watch: Practice Guideline for the Treatment of Patients with Major Depressive Disorder. 2nd ed. Washington, DC: American Psychiatric Association; 2005.
5. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with Citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28-40.
6. Quitkin FM, Petkova E, McGrath PJ, et al. When should a trial of fluoxetine for major depression be declared failed? Am J Psychiatry. 2003;160:734-740.
7. Bauer M, Bschor T, Pfennig A, et al. WFSBP Task force on unipolar depressive disorders. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry. 2007;8:67-104.
8. Rush AJ. STAR*D: what have we learned? Am J Psych. 2007;164:201-204.
9. Warden D, Trivedi MH, Wisniewski SR, et al. Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. Am J Psychiatry. 2007;164:1189-1197.
10. Olfson M, Marcus S, Tedeschi M. Continuity of antidepressant treatment for adults with depression in the United States. Am J Psych. 2006;163:101-108.
11. Lesser IM, Castro DB, Gaynes BN, et al. Ethnichy/race and outcome in the treatment of depression: results from STAR*D. Med Care. 2007;45:1043-1051.
12. Fava GA, Ruini C, Belaise C. The concept of recovery in major depression. Psychol Med. 2007;37:307-317.
13. Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry. 2006;163:1161-1172.
14. Trivedi MH, Daly EJ. Measurement-based care for refractory depression: a clinical decision support model for clinical research and practice. Drug Alcohol Depend. 2007;88(suppl 2):S61-S71.
15. Keitner GI, Ryan CE, Miller IW, Norman WH. Recovery and major depression: factors associated with twelve-month outcome. Am J Psychiatry. 1992;149;1127-1128.
16. Simon GE, Von Korff M, Barlow W. Health care costs of primary care patients with recognized depression. Arch Gen Psychiatry. 1995;52:850-856.
17. Stahl SM, Grady MM. Differences in mechanism of action between current and future antidepressants. J Clin Psych. 2003;64:13-17.
18. Thase ME, Blomgren SL, Birkett MA, Apter JT, Tepner RG. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry. 1997;58:16-21.
19. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354:1231-1242.
20. Rush AJ, Wisniewski SR, Warden D, et al. Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry. 2008;65:870-880.
21. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354:1243-1252.
22. Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry. 2006;163:1519-1530.
23. McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry. 2006;163:1531-1541.
24. Rush AJ, Thase ME, Dubé S. Research issues in the study of difficult-to-treat depression. Biol Psychiatry. 2003;53:743-753.
25. Hunter AM, Leuchter AF, Morgan ML, Cook IA. Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression. Am J Psychiatry. 2006;163:1426-1432.
26. Hunter AM, Ravikumar S, Cook IA, Leuchter AF. Changes in brain function (QEEG cordance) during placebo lead-in and SCL-90-R symptom dimension changes in MDD during randomized treatment with antidepressant or placebo. Acta Psychiatrica Scandinavica. 2009;119:266-273.
27. Price DD, Finniss DG, Benedetti F. A comprehensive review of the placebo effect: recent advances and current thought. Ann Rev Psychol. 2008;59:565-590.
28. Rutherford BR, Rose SA, Sneed JR, Roose SP. Study design affects participant expectations: a survey. J Clin Psychopharmacol. 2009;29:179-181.
29. Krell HV, Leuchter AF, Morgan M, et al. Subject expectations of treatment effectiveness and outcome of treatment with an experimental antidepressant. J Clin Psychiatry. 2004;65:1174-1179.
30. Aikens JE, Nease DE Jr, Nau DP, et al. Adherence to maintenance-phase antidepressant medication as a function of patient beliefs about medication. Ann Fam Med. 2005;3:23-30.
31. Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol. 2009;19:34-40.
32. Beck AT, Rush AJ, Shaw BF, Emery G. Cognitive Therapy of Depression. New York, NY: Guilford Publications; 1979.
33. Gaudiano BA, Miller IW. Dysfunctional cognitions in hospitalized patients with psychotic versus nonpsychotic major depression. Compr Psychiatry. 2007;48:357-365.
34. Abramson LY, Metalsky GI, Alloy LB. Hopelessness depression: a theory based subtype of depression. Psychol Rev. 1989;96:358-372.
35. Candrian M, Farabaugh A, Pizzagalli DA, et al. Perceived stress and cognitive vulnerability mediate the effects of personality disorder comorbidity on treatment outcome in major depressive disorder: a path analysis study. J Nerv Ment Dis. 2007;195:729-737.
36. Ader R, Felten DL, Cohen N. Psychoneuroimmunology. 2nd ed. San Diego, CA: Academic Press; 1991.
37. Ader R, Cohen N. Psychoneuroimmunology: conditioning and stress. Ann Rev Psychology. 1993;44:53-85.
38. Ginsburg BC, Lamb RJ. Reinforcement magnitude modulation of rate-dependent effects of fluvoxamine and desipramine in the rat. Behav Pharmacol. 2008;19:829-835.
39. Broadbear JH, Winger G, Cicero TJ, Woods JH. Effects of response contingent and noncontingent cocaine injection on hypothalamic-pituitary-adrenal activity in rhesus monkeys. J Pharmacol Exp Ther. 1999;290:393-402.
40. Tarpy RM. Contemporary Learning Theory and Research. New York, NY: McGraw-Hill Humanities/Social Sciences/Langua;1997.
41. Brody AL, Saxena S, Silverman DH, et al. Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine. Psychiatry Res. 1999;91:127-139.
42. Cook IA, Leuchter AF, Morgan M, et al. Early changes in prefrontal activity characterize clinical responders to antidepressants. Neuropsychopharmacology. 2002;27:120-131.
43. Khan A, Redding N, Brown WA. The persistence of the placebo response in antidepressant clinical trials. J Psychiatr Res. 2008;42:791-796.
44. Moertel CG, Taylor WF, Roth A, Tyce FA. Who responds to sugar pills? Mayo Clin Proc. 1976;51:96-100.
45. Batterman RC. Methodology of analgesic evaluation: experience with orphenadrine citrate compound. Curr Ther Res Clin Exp. 1965;7:639-647.
46. Amanzio M, Pollo A, Maggi G, Benedetti F. Response variability to analgesics: a role for non-specific activation of endogenous opioids. Pain. 2001;90:205-215.
47. Amanzio M, Benedetti F. Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems. J Neurosci 1999;19:484-494.
48. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry. 2003;160:636-645.
49. Hasler G, Drevets WC, Manji HK, Charney DS. Discovering endophenotypes for major depression. Neuropsychopharmacology. 2004;29:1765-1781.
50. Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry. 2008;165:342-351.
51. Nunes EV, Levin FR. Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA. 2004;291:1887-1896.
52. Duval F, Lebowitz BD, Macher JP. Treatments in depression. Dialogues Clin Neurosci. 2006;8:191-206.
53. Gould TD, Gottesman II. Psychiatric endophenotypes and the development of valid animal models. Genes Brain Behav. 2006;5:113-119.
54. Mayberg HS, Brannan SK, Mahurin RK, et al. Cingulate function in depression: a potential predictor of treatment response. Neuroreport. 1997;8:1057-1061.
55. Pizzagalli D, Pascual-Marqui RD, Nitschke JB, et al. Anterior cingulate activity as a predictor of degree of treatment response in major depression: evidence from brain electrical tomography analysis. Am J Psychiatry. 2001;158:405-415.
56. Canli T, Cooney RE, Goldin P, et al. Amygdala reactivity to emotional faces predicts improvement in major depression. Neuroreport. 2005;16:1267-1270.
57. Korb AS, Hunter AM, Cook IA, Leuchter AF. Rostral anterior cingulate cortex theta current density and response to antidepressants and placebo in major depression. Clin Neurophysiol. 2009;120:1313-1319.
58. Savitz JB, Drevets WC. Imaging phenotypes of major depressive disorder: genetic correlates. Neuroscience. 2009;164:300-330.
59. Schulz P, Berney P. Clinicians' predictions of patient response to psychotropic medications. Dialogues Clin Neurosci. 2004; 6:105-111.
60. Perlis RH, Iosifescu DV, Renshaw PF. Biological predictors of treatment response in affective illness. Psychiatr Clin North Am. 2003;26:323-344.
61. Kim H, Lim SW, Kim S, et al. Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression. JAMA. 2006;296:1609-1618.
62. McMahon FJ, Buervenich S, Charney D, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet. 2006;78:804-814.
63. Perlis RH, Moorjani P, Fagerness J, et al. Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR*D study. Neuropsychopharmacology. 2008;33:2810-2819.
64. Anguelova M, Benkelfat C, Turecki G. A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter: II. Suicidal behavior. Mol Psychiatry. 2003;8:646-653.
65. Perlis RH, Patrick A, Smoller JW, Wang PS. When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study. Neuropsychopharmacology. 2009;34:2227-2236.
66. Malhotra AK, Murphy GM, Jr., Kennedy JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry. 2004;161:780-796.
67. Gottesman I, Shields J. Schizophrenia and Genetics: a Twin Study Vantage Point. New York, NY: Academic Press; 1972.
68. Nierenberg AA, McLean NE, Alpert JE, Worthington JJ, Rosenbaum JF, Fava M. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry. 1995;152:1500-1503.
69. Rojo JE, Gibert K, Cobo J, Rodriguez-Cano E, Vallejo J. Onset of antidepressant action: a pharmacological question? Hum Psychopharmacol. 2005;20:425-433.
70. Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action. Arch Gen Psychiatry. 2006; 63:1217-1223.
71. Papakostas GI, Perlis RH, Scalia MJ, Petersen TJ, Fava M. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. J Clin Psychopharmacol. 2006;26:56-60.
72. Stewart JW, Quitkin FM, McGrath PJ, et al. Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo. Arch Gen Psychiatry. 1998;55:334-343.
73. Nierenberg AA, Quitkin FM, Kremer C, et al. Placebo-controlled continuation treatment with mirtazapine: acute pattern of response predicts relapse. Neuropsychopharmacology. 2004;29:1012-8102.
74. Szegedi A, Jansen WT, van Willigenburg AP, et al. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry. 2009;70:344-353.
75. Knott VJ, Telner JI, Lapierre YD, et al. Quantitative EEG in the prediction of antidepressant response to imipramine. J Affect Disord. 1996; 39:175-184.
76. Ulrich G, Haug H-J, Fahndrich. Acute versus chronic EEG effects of maprotiline- and in domipramine-treated depressive inpatients and the prediction of therapeutic outcome. J Affect Disord. 1994;32:213-217.
77. Ulrich, G, Haug, H, Stieglitz, R, Fahndrich, E. Are there distinct biochemical subtypes of depression? EEG characteristics of clinically defined on-drug responders and non-responders. J Affect Disord. 1988;15:181-185.
78. Leuchter AF, Uijtdehaage SH, Cook IA, et al. Relationship between brain electrical activity and cortical perfusion in normal subjects. Psychiatry Res. 1999;90:125-140.
79. Asada H, Fukuda Y, Tsunoda S, et al. Frontal midline theta rhythms reflect alternative activation of prefrontal cortex and anterior cingulate cortex in humans. Neurosci Lett. 1999;274:29-32.
80. Leuchter AF, Cook IA, Marangell LB, et al. Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: results of the BRITE-MD study. Psychiatry Res. 2009;169:124-131.
81. Leuchter AF, Cook IA, Gilmer WS, et al. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in Major Depressive Disorder. Psychiatry Res. 2009;169:132-138.
82. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995;310:452-454.
83. Sinclair JC, Cook RJ, Guyatt GH, et al. When should an effective treatment be used? Derivation of the threshold number needed to treat and the minimum event rate for treatment. J Clin Epidemiol. 2001;54:253-262.
84. Papakostas, GI, Thase, ME, Fava, M, et al. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry. 2007;62:1217-1227.
85. Altar CA, Vawter MP, Ginsberg SD. Target identification for CNS diseases by transcriptional profiling. Neuropsychopharmacology. 2009;34:18-54.
86. Tanis KQ, Duman RS. Intracellular signaling pathways pave roads to recovery for mood disorders. Ann Med. 2007;39:531-544.
87. Begemann M, Sargin D, Rossner MJ, et al. Episode-specific differential gene expression of peripheral blood mononuclear cells in rapid cycling supports novel treatment approaches. Mol Med. 2008;14:546-552.
88. Iga J, Ueno S, Yamauchi K, et al. Serotonin transporter mRNA expression in peripheral leukocytes of patients with major depression before and after treatment with paroxetine. Neurosci Lett. 2005;389:12-16.
89. Iga J, Ueno S, Yamauchi K, Numata S, et al. Gene expression and association analysis of LIM (PDLIM5) in major depression. Neurosci Lett. 2006;400:203-207.
90. Iga J, Ueno S, Yamauchi K, et al. Gene expression and association analysis of vascular endothelial growth factor in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:658-663.
91. Iga J, Ueno S, Yamauchi K, et al. Altered HDAC5 and CREB mRNA expressions in the peripheral leukocytes of major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:628-632.
92. Iga J, Ueno S, Ohmori T. Molecular assessment of depression from mRNAs in the peripheral leukocytes. Ann Med. 2008;40:336-342.
93. Sun X, Young LT, Wang JF, et al. Identification of lithium-regulated genes in cultured lymphoblasts of lithium responsive subjects with bipolar disorder. Neuropsychopharmacology. 2004;29:799-804.
94. Tang Y, Glauser TA, Gilbert DL, et al. Valproic acid blood genomic expression patterns in children with epilepsy - a pilot study. Acta Neurol Scand. 2004;109:159-168.